The ozonation of N-Boc-protected 3-methylidene-4-phenyl-5-(trifluoromethyl)pyrrolidin-2-one resulted in its transformation into 3-hydroxy-4-phenyl-5-(trifluoromethyl)-3-pyrrolin-2-one. Catalytic hydrogenation of its O-Boc-protected derivative introduced a way to reduce the double bond in combination with elimination of the hydroxy group leading to the formation of 4-phenyl-5-(trifluoromethyl)pyrrolidin-2-one as an intermediate in the synthesis of fluorinated E1R structural derivative 2-[5-oxo-3-phenyl-2-(trifluoromethyl)pyrrolidin-1-yl]acetamide.
Similar content being viewed by others
References
(a) Vavers, E.; Zvejniece, L.; Maurice, T.; Dambrova, M. Front. Pharmacol. 2019, 10, 223. (b) Maurice, T.; Su, T.-P. Pharmacol. Ther. 2009, 124, 195.
(a) Zvejniece, L.; Vavers, E.; Svalbe, B.; Vilskersts, R.; Vorona, M.; Veinberg, G.; Misane, I.; Stonans, I.; Kalvinsh, I.; Dambrova, M. Br. J. Pharmacol. 2014, 171, 761. (b) Zvejniece, L.; Dambrova, M.; Svalbe, B.; Vavers, E.; Kalvinsh, I.; Veinbergs, G.; Stonans, I.; Misane, I. EU Patent 3127539; Chem. Abstr. 2017, 166, 223481.
(a) Veinberg, G.; Vorona, M.; Zvejniece, L.; Vilskersts, R.; Vavers, E.; Liepinsh, E.; Kazoka, H.; Belyakov, S.; Mishnev, A.; Kuznecovs, J.; Vikainis, S.; Orlova, N.; Lebedev, A.; Ponomaryov, Y.; Dambrova, M. Bioorg. Med. Chem. 2013, 21, 2764. (b) Guo, L.; Zhao, J.; Jin, G.; Zhao, B.; Wang, G.; Zhang, A.; Zhen, X. Mol. Pharmacol. 2013, 83, 577.
Itoh, Y.; Beaulieu, M.; Kebabian, J. W. Eur. J. Pharmacol. 1984, 100, 119.
Gouliaev, A. H.; Senning, A. Brain Res. Rev. 1994, 19, 180.
(a) Yerien, D. E.; Bonesi, S.; Postigo, A. Org. Biomol. Chem. 2016, 14, 8398. (b) Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J. L.; Soloshonok, V. A.; Izawa, K.; Liu, H. Chem. Rev. 2016, 116, 422.
(a) Baasner, B.; Marhold, A.; Negele, M. J. Fluorine Chem. 1990, 46, 161. (b) Negele, M.; Baasner, B.; Bertran, H.-J.; Hartwig, J. EU Patent 475236; Chem. Abstr. 1992, 117, 7798.
Li, X.; Su, J.; Liu, Z.; Zhu, Y.; Dong, Z.; Qiu, S.; Wang, J.; Lin, L.; Shen, Z.; Yan, W.; Wang, K.; Wang, R. Org. Lett. 2016, 18, 956.
Bower, J. F.; Williams, A. J.; Woodward, H. L.; Szeto, P.; Lawrence, R. M.; Gallagher, T. Org. Biomol. Chem. 2007, 5, 2636.
Shymanska, N. V.; Pierce, J. G. Org. Lett. 2017, 19, 2961.
Hayashi, T.; Maurice, T.; Su, T.-P. J. Pharmacol. Exp. Ther. 2000, 293, 788.
Sheldrick, G. M. Acta Crystallogr., Sect. A: Found. Adv. 2015, A71, 3.
Bourhis, L. J.; Dolomanov, O. V.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H. Acta Crystallogr., Sect. A: Found. Adv. 2015, A71, 59.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Published in Khimiya Geterotsiklicheskikh Soedinenii, 2020, 56(10), 1297–1301
Supplementary Information
ESM 1
(PDF 2073 kb)
Rights and permissions
About this article
Cite this article
Kuznecovs, J., Baskevics, V., Orlova, N. et al. Synthesis of a Fluorinated Derivative of Sigma-1 Receptor Modulator E1R: 2-[5-oxo-3-phenyl-2-(trifluoromethyl)pyrrolidin-1-yl]Acetamide. Chem Heterocycl Comp 56, 1297–1301 (2020). https://doi.org/10.1007/s10593-020-02814-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10593-020-02814-1